Genzyme’s Termeer May Follow Health-Care CEOs to Private EquityMeg Tirrell and Alex Nussbaum
Genzyme Corp.’s chief executive officer, Henri A. Termeer, will leave his post of 26 years after Sanofi-Aventis SA closes its $20.1 billion purchase of his company. He may not be out of a job for long.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.